SCHEMBL19096625

SCHEMBL19096625

O=C1/C(=C/c2ccc3c(c2)OCCO3)S/C(=N\Cc2ccc(F)cc2)N1c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.47
▸ FAAH O00519 1/20 0.45
▸ GSK3B P49841 1/20 0.44
▸ KMT2A Q03164 5/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ PIM1 P11309 2/20 0.42
▸ DYRK2 Q92630 2/20 0.42
▸ BLM P54132 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ DYRK3 O43781 1/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ S1PR1 P21453 3/20 0.41
▸ S1PR3 Q99500 3/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ THRB P10828 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19096607 0.95 MGAM (0.46) CFTRFAAHGSK3BKMT2AMEN1
SCHEMBL19096247 0.95 MGAM (0.46) CFTRFAAHGSK3BKMT2AMEN1
SCHEMBL19096377 0.95 S1PR1 (0.45) CFTRFAAHGSK3BKMT2AMEN1
SCHEMBL17295267 0.95 S1PR1 (0.47) CFTRFAAHGSK3BMAPTPIM1
SCHEMBL17295265 0.95 S1PR1 (0.47) CFTRFAAHGSK3BMAPTPIM1
SCHEMBL19096567 0.93 FAAH (0.49) CFTRFAAHKMT2AMEN1SMN1; SMN2
SCHEMBL17302125 0.88 S1PR1 (0.51) CFTRGSK3BKMT2AMEN1MAPT
SCHEMBL19096526 0.85 FAAH (0.58) CFTRFAAHGSK3BKMT2AMEN1
SCHEMBL19096416 0.85 FAAH (0.50) CFTRFAAHKMT2AMEN1MAPT
SCHEMBL19096560 0.84 S1PR1 (0.49) CFTRFAAHKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4011879-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2022-06-15 — — EP disclosed
EP-3148990-B1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2022-01-19 — — EP disclosed
US-10774077-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2020-09-15 — — US disclosed
US-10774077-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2020-09-15 — — US disclosed
US-10392377-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2019-08-27 — — US disclosed
US-10392377-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2019-08-27 — — US disclosed
US-20190119265-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2019-04-25 — — US disclosed
US-20190119265-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2019-04-25 — — US disclosed
US-10155754-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors UNIVERSITAT BERN (CH) 2018-12-18 — — US disclosed
US-20170197952-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-07-13 — — US disclosed
US-20170197952-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-07-13 — — US disclosed
US-20170197952-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197952-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION GRIN2B, IL1B, GRIA4 CFTR 2690/4885FAAH 240/4885GSK3B 455/4885
US-10392377-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors CNR2, CNR1, GPR18 CFTR 3380/4885FAAH 4/4885GSK3B 1770/4885
US-20190119265-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION GRIN2B, IL1B, GRIA4 CFTR 2667/4885FAAH 245/4885GSK3B 437/4885
US-10155754-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors CNR2, CNR1, GPR18 CFTR 3380/4885FAAH 4/4885GSK3B 1770/4885
US-10774077-B2 Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors CNR2, CNR1, GPR18 CFTR 3380/4885FAAH 4/4885GSK3B 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback